The company said, “Based on current internal planning assumptions, the Company expects fiscal 2026 revenue of approximately $150M, representing a conservative baseline outlook reflecting currently contracted demand and visible partner activity. This guidance is intended to represent a baseline or ‘floor-case’ scenario and assumes continued execution across the Company’s existing pharmacy operations and digital health platform. The guidance excludes any potential incremental contributions from acquisitions, new geographic market entries, or commercial arrangements that are not currently operational as of the date of this release.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HYDTF:
- Hydreight Raises $15 Million in Oversubscribed Bought-Deal to Accelerate U.S. Digital Health Expansion
- Hydreight Raises C$10 Million in Bought Deal to Accelerate U.S. Digital Healthcare Growth
- Hydreight Moves Into At-Home STI Testing With Exclusive Deal and 50,000 Pre-Orders
- Hydreight enters distribution agreement with Health Screen Collective
- Hydreight Beats 2025 Targets With 1.3 Million Orders and Rapid License Growth